

**CA Hull Investments**

C/o Apex Fund & Corporate Services (Mauritius) Ltd  
6th Floor, Two Tribeca, Tribeca Central, Trianon 72261, Mauritius  
•Tel: (230) 404 3900 • Fax: (230) 454 6824

December 17, 2025

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001  
Scrip Code: 512529

**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra-Kurla Complex,  
Bandra (East),  
Mumbai - 400 051  
Scrip Symbol: SEQUENT

**Sequent Scientific Limited**

3rd Floor, Srivallis Corporate, Plot No. 290, SYN  
33 34P TO 39, Guttala Begumpet, Jubilee Hills,  
Shaikpet, Hyderabad, Telangana, 500033

**Subject: Disclosure under Regulation 29(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011 ("SEBI Takeover Regulations").**

**Ref.: Composite scheme of amalgamation among Sequent Scientific Limited ("Sequent" or "TC"), Viyash Life Sciences Private Limited ("Viyash"), Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Geninn Life Sciences Private Limited and Sequent Research Limited and their respective shareholders and creditors ("Scheme").**

Dear Sir/Ma'am,

Pursuant to Scheme, sanctioned by the Hon'ble National Company Law Tribunal, Hyderabad bench *vide* its order dated November 18, 2025, Sequent has, on December 16, 2025, allotted equity shares to the shareholders of Viyash, in the share exchange ratio as set out in the Scheme, i.e., 56 (Fifty Six) fully paid-up equity shares of Sequent of the face value of INR 2/- (Indian Rupees Two only), for every 100 (One Hundred) fully paid-up equity shares of INR 10 (Indian Rupees Ten only) each held by such member in Viyash. Accordingly, pursuant to such allotment Sequent has allotted **13,61,60,231** (Thirteen Crore Sixty-One Lakh Sixty Thousand Two Hundred and Thirty-One) equity shares of Sequent to us, each fully paid up and having face value of INR 2/- (Indian Rupees Two) constituting **31.20%** (Thirty-One point Two percent) of the total paid up share capital of Sequent.

In compliance with Regulation 29(1) of the SEBI Takeover Regulations, a disclosure with relevant details in the prescribed format is enclosed herewith for your reference and records.

Kindly acknowledge receipt of this intimation.

Thanking you,

Yours faithfully,  
For **CA Hull Investments**



Name: Purnima Boyjonauth Bhogun  
Designation: Director

**CA Hull Investments**

C/o Apex Fund & Corporate Services (Mauritius) Ltd  
 6th Floor, Two Tribeca, Tribeca Central, Trianon 72261, Mauritius  
 •Tel: (230) 404 3900 • Fax: (230) 454 6824

**Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

***Part A- Details of the acquisition***

Name of the Target Company (TC)	Sequent Scientific Limited		
Name (s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	<b>Acquirer:</b> CA Hull Investments <b>PAC:</b> CA Harbor Investments		
Whether the acquirer belongs to the promoter/promoter group	Yes		
Names of the Stock Exchange(s) where the shares of the TC are listed	(a) BSE Limited; and (b) National Stock Exchange of India Limited.		
Details of the acquisitions as follows	<b>Number</b>	<b>% w.r.t. total share/voting capital wherever applicable*</b>	<b>% w.r.t total diluted share/voting capital of the TC**</b>
<b><i>Before the acquisition under consideration, holding of acquirer along with PACs of:</i></b>			
a) Shares carrying voting rights			
- CA Hull Investments	-	-	-
- CA Harbor Investments	13,16,80,103	52.33%	49.59%
b) Shares in the nature of encumbrance (pledge/ lien / non disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
<b>e) Total (a+b+c+d)</b>	<b>13,16,80,103</b>	<b>52.33%</b>	<b>49.59%</b>
<b><i>Details of acquisition</i></b>			
a) Shares carrying voting rights			
- CA Hull Investments	13,61,60,231	31.2%#	28.2%#
- CA Harbor Investments	-	-	-
b) Shares in the nature of encumbrance (pledge/ lien/ non disposal undertaking/ others)	-	-	-
c) Voting rights (VR)	-	-	-

**CA Hull Investments**

C/o Apex Fund & Corporate Services (Mauritius) Ltd  
 6th Floor, Two Tribeca, Tribeca Central, Trianon 72261, Mauritius  
 •Tel: (230) 404 3900 • Fax: (230) 454 6824

otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
<b>e) Total (a+b+c+d)</b>	<b>13,61,60,231</b>	<b>31.2%<sup>#</sup></b>	<b>28.2%<sup>#</sup></b>
<i><b>After the acquisition, holding of acquirer with PACs:</b></i>			
a) Shares carrying voting rights	26,78,40,334	61.4%	55.5%
b) Shares in the nature of encumbrance (pledge/ lien/ non disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
<b>e) Total (a+b+c+d)</b>	<b>26,78,40,334</b>	<b>61.4%</b>	<b>55.5%</b>
Mode of acquisition (e.g. open market/ public issue / rights issue / preferential allotment / inter-se transfer / encumbrance, etc.)	Allotment pursuant to the composite scheme of amalgamation among the TC, Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Geninn Life Sciences Private Limited, Sequent Research Limited and their respective shareholders and creditors, approved by the Hon'ble National Company Law Tribunal, Hyderabad bench <i>vide</i> its order dated November 18, 2025, in accordance with Sections 230 to 232 of the Companies Act, 2013 read with the relevant rules and regulations notified thereunder.		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	N.A.		
Date of acquisition of / date of receipt of intimation of allotment of shares / VR / warrants / convertible securities / any other instrument that entitles the acquirer to receive shares in the TC.	December 16, 2025		

**CA Hull Investments**

C/o Apex Fund & Corporate Services (Mauritius) Ltd  
 6th Floor, Two Tribeca, Tribeca Central, Trianon 72261, Mauritius  
 •Tel: (230) 404 3900 • Fax: (230) 454 6824

Equity share capital / total voting capital of the TC before the said acquisition.	25,41,12,649 shares of INR 2/- each aggregating to INR 50,82,25,298.
Equity share capital/ total voting capital of the TC after the said acquisition	43,60,34,463 shares of INR 2/- each aggregating to INR 87,20,68,926.
Total diluted share/voting capital of the TC after the said acquisition	48,23,24,681 shares of INR 2/- each aggregating to INR 96,46,49,362.

- (\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.
- (\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.
- (#) This allotment is pursuant to the composite scheme of amalgamation among the TC, Viyash Life Sciences Private Limited (“**Viyash**”), Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Geninn Life Sciences Private Limited, Sequent Research Limited and their respective shareholders and creditors (“**Scheme**”), approved by the Hon’ble National Company Law Tribunal, Hyderabad bench, *vide* its order dated November 18, 2025. Pursuant to the Scheme, the TC has allotted equity shares to the shareholders of Viyash, in the share exchange ratio of 56:100, i.e., 56 (Fifty Six) fully paid-up equity shares of the TC of the face value of INR 2/- (Indian Rupees Two only), for every 100 (One Hundred) fully paid-up equity shares of INR 10 (Indian Rupees Ten only) each held by such member in Viyash, in accordance with the terms of the Scheme. Accordingly, the TC has allotted 13,61,60,231 (Thirteen Crore Sixty-One Lakh Sixty Thousand Two Hundred and Thirty-One) equity shares of INR 2/- (Indian Rupees Two only) each to CA Hull Investments, and consequent to such allotment, CA Hull Investments also forms part of the promoter group of TC.

**Part B**